Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. clinical trials
A subsidiary of Sino Biopharmaceutical Limited
The registry lists 53 studies whose lead sponsor is Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. 29 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
Where
- China
- 53
Registry sponsor names on this page
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.53 studies
Something wrong with this grouping? Tell us on the Sino Biopharmaceutical Limited page.
Studies
Recruiting first, then most recently updated. Showing 50 of 53. List all 53 → · All Sino Biopharmaceutical Limited studies →
- A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.RecruitingNCT07653685Phase 1/2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque PsoriasisRecruitingNCT07724366Phase 3
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic ArthritisRecruitingNCT07406035Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid TumorsRecruitingNCT07512583Phase 1/2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- TQB2930 Injection for the Treatment of HER2-positive Advanced Breast CancerRecruitingNCT07047365Phase 3
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's DiseaseRecruitingNCT06754891Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract CancerRecruitingNCT06431490Phase 1/2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerRecruitingNCT07043725Phase 3
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based DrugsNot yet recruitingNCT07483684Phase 3
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant TumorsRecruitingNCT07043751Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Clinical Studies for the Treatment of Advanced Solid TumorsRecruitingNCT06825494Phase 1/2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsRecruitingNCT07179679Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene AbnormalityRecruitingNCT06496490Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic NeoplasmsRecruitingNCT06767813Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast CancerRecruitingNCT07008976Phase 3
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal CancerRecruitingNCT07044908Phase 1/2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic MalignanciesRecruitingNCT07113925Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal AdenocarcinomaRecruitingNCT06767800Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic AdvancedRecruitingNCT06798207Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast CancerRecruitingNCT07003074Phase 3
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)RecruitingNCT06962267Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant TumorsNot yet recruitingNCT06948539Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Clinical Trial of TQB2922 for Injection in Patients With Advanced CancersRecruitingNCT06188624Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Study of TQB2029 for Injection in Subjects With Multiple MyelomaRecruitingNCT06700395Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast CancerRecruitingNCT06452706Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive LeukemiaNot yet recruitingNCT06672263Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung CancersNot yet recruitingNCT06585059Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)RecruitingNCT06569524Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Clinical Trial Evaluating the Safety of the TQB2103 for InjectionRecruitingNCT05867563Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.CompletedNCT06089278Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast CancerCompletedNCT06115902Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia AActive, not recruitingNCT06297655Phase 3
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects.TerminatedNCT06143423Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Clinical Trial to Evaluate the Tolerance of TQB2210 InjectionCompletedNCT06929195Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseActive, not recruitingNCT06789289Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic RhinitisCompletedNCT07052097Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Treatment of Moderate to Severe Plaque PsoriasisCompletedNCT06542614Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)TerminatedNCT06106841Phase 1/2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid TumorsTerminatedNCT06438783Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal PolypsCompletedNCT06451640Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Clinical Trial of the TQB2102 Injection in Patients With Advanced CancersActive, not recruitingNCT05735496Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)Active, not recruitingNCT06433531Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Trial of TQH3906 Capsules in Healthy VolunteersCompletedNCT06230588Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Study of TQH2929 in Healthy Adult SubjectsCompletedNCT06156280Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Trial of TQC2938 Injection in Healthy Adult SubjectsActive, not recruitingNCT06449859Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade SarcomaTerminatedNCT05262101Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic CarcinomaTerminatedNCT05193604Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological TumorsStatus unknownNCT05489276Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult SubjectsStatus unknownNCT05409326Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Clinical Trial of the TQB2930 Injection in Patients With Advanced CancersStatus unknownNCT05380882Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.